Actinogen is developing a revolutionary oral therapeutic, Xanamem^®, which controls levels of the “stress hormone” cortisol in the brain, with the goal of improving the lives of patients and their families. Topline results from our first pivotal Alzheimer’s trial, evaluating its potential to slow disease progression, are expected in November 2026.

ACW senior management presentation at AAIC & internationally

Actinogen will conduct a series of key stakeholder meetings over the coming weeks with potential global and regional commercialization partners in Alzheimer’s disease, key opinion leaders and international biotech experts. Many of these meetings will be
conducted at the Alzheimer’s Association International Conference (AAIC) in London, UK, from July 12-15, 2026

ACW third positive XanaMIA trial data committee review

Actinogen is pleased to announce receipt of the positive recommendation of the XanaMIA phase 2b/3 trial’s independent Data Monitoring Committee (DMC) to continue the trial without amendment. Topline final trial results are expected in November this year.

ACW presents XanaMIA population and screening data at ADRF

Actinogen is pleased to announce the presentation of an academic poster highlighting screening efficiency and baseline population characteristics from the fully enrolled XanaMIA phase 2b/3 trial of Xanamem® (emestedastat) in patients with mild to moderate Alzheimer’s disease (AD). The poster is being presented today at the Australian Dementia Network’s Australian Dementia Research Forum (ADRF) in Sydney, Australia

ACW CEO options exercise and expiry reminder

ACW wishes to remind
option holders that two tranches of unlisted options, both exercisable at $0.0375 per option, are expiring in September 2026, with further details available in the announcement. 

ACW March 2026 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C f or the three-month period ended 31 March 2026.

ACW XanaMIA Alzheimers open label trial commences

ACW has announced the commencement of the open‑label extension phase of the XanaMIA AD trial, with the treatment of the first eligible participant in Australia. The OLE enables all current and former participants who have completed the randomized trial to receive active Xanamem 10 mg once daily for up to 25 months, with no placebo control group.

ACW successfully completes $16.8m Placement and SPP

Actinogen is pleased to announce that its share purchase plan (SPP) is now complete, with $4.8 million raised from existing shareholders.

This brings total funding from this capital raising round to $16.8 million, when combined with the $12.0 million in placement funding announced on 2 February 2026.